Navigation Links
Cancer: Trapping the escape artist
Date:5/11/2010

LA JOLLA, Calif., May 11, 2010 -- Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.

In a paper published online in the journal Cell Death and Disease on May 6, Maurizio Pellecchia, Ph.D., and colleagues outline how the six anti-apoptotic proteins in the Bcl-2 family are expressed differently in different cancers. As a result, any therapy designed to defeat these proteins, and thus enhance the cell death caused by most cancer treatments, must target the exact anti-apoptotic protein the cancer is expressing to be effective. However, even targeting the right protein might not be enough, as cancers often express more than one and can select for an "escape" protein and continue to thrive.

"You need to inhibit all six of the anti-apoptotic proteins members of the Bcl-2 family to have a compound with therapeutic potential," says Dr. Pellecchia.

Related research may have solved that problem. The Pellecchia laboratory, in collaboration with Coronado Biosciences and Virginia Commonwealth University, has been working on just such a pan-Bcl-2 inhibitor, and may have found it in a compound called BI-97C1. A paper published online on May 5 in the Journal of Medicinal Chemistry describes how BI-97C1, an optically pure derivative of a cottonseed extract called gossypol, inhibits all six anti-apoptotic Bcl -2 family proteins. This broad spectrum approach could make current cancer treatments more effective by controlling all six of these proteins and allowing malignant cells to die.

"When we tested BI-97C1 against human prostate cancer in mice, the cancer was completely wiped out, even with one tenth the dose we had used with previous compounds," says Dr. Pellecchia.

BI-97C1 is currently licensed to Coronado Biosciences, a private, clinical stage biotech company focused on new cancer treatments. Coronado's pan Bcl-2 inhibitor program is expected to enter clinical trials soon. "We have a very productive collaboration with Dr. Pellecchia," says R.J. Tesi, M.D., president and CEO of Coronado Biosciences. "His work demonstrates the importance of inhibiting all six Bcl-2 pro-survival proteins and demonstrates how rational drug design can optimize the development of targeted therapies to treat cancer. We are anxious to move BI-97C1 from pre-clinical development into patients."


'/>"/>

Contact: Josh Baxt
jbaxt@sanfordburnham.org
858-795-5236
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Related biology news :

1. Prostate cancer: Watchful wait or vaccinate?
2. Scientists discover how cigarette smoke causes cancer: Study points to new treatments, safer tobacco
3. Stem cells and cancer: cancer pathways that also control the adult stem cell population
4. Hispanic women and breast cancer: An understudied group
5. Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
6. Cancer: Another step towards medication
7. Early detection of lung cancer: New data presented at multidisciplinary meeting
8. From cars to cancer: UH professor employs auto industry tools for tumor therapy
9. Cancer: The cost of being smarter than chimps?
10. Cancer: Primitive gene discovered
11. Milk and risk of renal cell cancer: Genetic research sheds new light
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology: